Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
…, H Poustchi, TD Quang, H Qureshi, A Ramji… - The lancet …, 2018 - thelancet.com
Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (…
to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (…
Burden of disease and cost of chronic hepatitis C virus infection in Canada
…, K Kaita, P Marotta, K Peltekian, A Ramji… - Canadian Journal of …, 2014 - hindawi.com
BACKGROUND: Chronic infection with hepatitis C virus (HCV) is a major cause of cirrhosis,
hepatocellular carcinoma and liver transplantation.OBJECTIVE: To estimate the burden of …
hepatocellular carcinoma and liver transplantation.OBJECTIVE: To estimate the burden of …
[HTML][HTML] Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection
…, SL Flamm, CL Cooper, A Ramji… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients who are chronically infected with hepatitis C virus (HCV) and who do
not have a sustained virologic response after treatment with regimens containing direct-acting …
not have a sustained virologic response after treatment with regimens containing direct-acting …
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
…, PJ Pockros, A Tran, J Yozviak, N Reau, A Ramji… - Jama, 2015 - jamanetwork.com
Importance Effective and well-tolerated, interferon-free regimens are needed for treatment
of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. Objective All-oral …
of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. Objective All-oral …
[HTML][HTML] The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver
…, M Bilodeau, KW Burak, C Cooper, M Klein, A Ramji… - Cmaj, 2018 - Can Med Assoc
The treatment of hepatitis C has become safer, better tolerated and more effective owing to
the availability of direct-acting antivirals for nearly all patients; this guideline advocates …
the availability of direct-acting antivirals for nearly all patients; this guideline advocates …
[HTML][HTML] Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity
LAP Krassenburg, R Maan, A Ramji, MP Manns… - Journal of …, 2021 - Elsevier
Background & Aims HCV-infected patients with cirrhosis achieve high sustained virological
response (SVR) rates with direct-acting antivirals (DAAs) even after hepatic decompensation. …
response (SVR) rates with direct-acting antivirals (DAAs) even after hepatic decompensation. …
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3 …
…, SH Ahn, WL Chuang, WY Tak, A Ramji… - The lancet …, 2020 - thelancet.com
Background Treatment with tenofovir disoproxil fumarate has been associated with renal
toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B …
toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B …
Transplant immunosuppressive agents in non‐transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with …
N Chatur, A Ramji, VG Bain, MM Ma… - Liver …, 2005 - Wiley Online Library
Background: Conventional treatment of autoimmune hepatitis consists of either prednisone
alone or in combination with azathioprine. Ten to 20% of patients do not respond to or are …
alone or in combination with azathioprine. Ten to 20% of patients do not respond to or are …
The population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC)
Background Population-level monitoring of hepatitis C virus (HCV) infected people across
the cascade of care identifies gaps in access and engagement in care and treatment. We …
the cascade of care identifies gaps in access and engagement in care and treatment. We …
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts
…, D Ouzan, G Papatheodoridis, A Ramji… - Liver …, 2020 - Wiley Online Library
Background and aims Achieving sustained virological response (SVR; cure) in hepatitis C
patients using a simple regimen is key to making elimination by 2030 possible. In the largest …
patients using a simple regimen is key to making elimination by 2030 possible. In the largest …
